Retatrutide appears to be a new pharmaceutical in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, a